ArticleJournal of neuro-oncology2025
The prognostic and protective roles of heart-rate variability in glioblastoma: making GBM less vague.
Article in Journal of neuro-oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeRecent data has shown the role of vagal nerve activity in cancer prognosis. This study examined the prognostic value of vagal nerve activity in patients with newly diagnosed glioblastoma.
methodsEighty-eight patients underwent a surgical resection or biopsy of glioblastoma in a single institution between 2003 and 2023. Inclusion criteria were: (1) age over 18; (2) diagnosed with newly diagnosed glioblastoma; (3) having an ECG prior to surgery. The predictor was vagal nerve activity indexed by heart rate variability (HRV) and obtained retroactively from 10 s ECGs. The main endpoint was overall survival (OS).
resultsHRV significantly predicted OS independent of confounders such as age, performance status, or extent of tumor resection (EOR), but only among younger patients (≤ 65 years old). Patients with low and high HRV had OS of 13.2 and 20.2 months, respectively (p < 0.05). We found evidence for a moderating effect of HRV in relation to other prognostic factors. Specifically, EOR predicted death only in patients with low HRV, but not with high HRV. Similarly, KPS tended to predict death only in patients with low, but not high HRV.
conclusionsIn this study, we have shown for the first time the clinical and prognostic value of vagal nerve activity indexed by measurement of HRV in patients with newly diagnosed glioblastoma. If replicated in prospective studies, vagal nerve activity may have the potential to be a new therapeutic target in newly diagnosed glioblastoma.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.